Genomics Law Report's Dan Vorhaus questions the distinctions in the FDA's policy on direct-to-consumer genetic testing kits. In a comment to the New York Times, Vorhaus says, the FDA seems to be singling out over-the-counter tests for regulatory review. But, Vorhaus asks, is point of sale really an appropriate distinction to make?